A5040537906- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- MicroRNA in disease regulation
- Ovarian cancer diagnosis and treatment
- Genetic Associations and Epidemiology
- Ubiquitin and proteasome pathways
- Immunotherapy and Immune Responses
- Genomics and Rare Diseases
- Phagocytosis and Immune Regulation
- Cancer-related gene regulation
- Pancreatic and Hepatic Oncology Research
- Cancer-related molecular mechanisms research
- interferon and immune responses
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- HIV Research and Treatment
- Esophageal Cancer Research and Treatment
- IL-33, ST2, and ILC Pathways
- Adenosine and Purinergic Signaling
- Immunodeficiency and Autoimmune Disorders
Mater Research
2019-2024
The University of Queensland
2018-2024
Translational Research Institute
2019-2024
Abstract Blockade of the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse. The impact digital gene expression was tested 309 patients with DLBCL treated standard chemoimmunotherapy. Cellular distribution protein determined by immunohistochemistry and flow cytometry. In tumor-infiltrating lymphocytes (TILs), highest on CD4+ regulatory T cells (Tregs) also highly expressed CD8+ compared non-Tregs (both P = .008). LAG3high TILs were...
Tumor cells orchestrate their microenvironment. Here, we provide biochemical, structural, functional, and clinical evidence that Cathepsin S (CTSS) alterations induce a tumor-promoting immune microenvironment in follicular lymphoma (FL). We found CTSS mutations at Y132 6% of FL (19/305). Another 13% (37/286) had amplification, which was associated with higher expression. lead to accelerated autocatalytic conversion from an enzymatically inactive profrom active increased substrate cleavage,...
Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder [PTLD]) is a highly aggressive non-Hodgkin lymphoma. It typically treated with high-dose methotrexate-based regimens. Outcomes are dismal and clinical trials lacking. almost always Epstein–Barr virus (EBV) associated. Two patients (CA1-2) presented EBV-associated PCNSL after renal transplant. CA1 was on hemodialysis had prior disseminated cryptococcus...
Data on the prognostic impact of pretherapy 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) in follicular lymphoma (FL) is conflicting. The predictive utility total metabolic tumor volume (TMTV) and maximum standardized uptake value (SUVmax) outcome appears to vary between regimens. Chemoimmunotherapies extent T-cell depletion they induce. role intratumoral T cells FDG-PET parameters undefined. We assessed quantified by multiple methodologies. Low associated with approximately...
Drugs selectively targeting replication stress have demonstrated significant preclinical activity, but this has not yet translated into an effective clinical treatment. Here we report that increased with a combination of Checkpoint kinase 1 inhibitor (CHK1i) subclinical dose hydroxyurea targets also promotes pro-inflammatory cytokine/chemokine expression is independent cGAS-STING pathway activation and immunogenic cell death in human murine melanoma cells. In vivo, drug induces tumour...
// Qingyan Cui 1 , Frank Vari Alexandre S. Cristino Carlos Salomon 2, 3 Gregory E. Rice 2 Muhammed B. Sabdia Dominic Guanzon Palma Marina Mathew Dipti Talaulikar 4, 5 Sanjiv Jain 4 Erica Han Mark Hertzberg 6 Clare Gould Pauline Crooks Gayathri Thillaiyampalam Colm Keane 1, 7 and Maher K. Gandhi University of Queensland Diamantina Institute, Brisbane, QLD, Australia Centre for Clinical Research, Concepción, Chile Canberra Hospital, Garran, ACT, National Medical School, Prince Wales...
<b><i>Introduction:</i></b> Hodgkin lymphoma (HL) is deficient in major histocompatibility complex class I, rendering it susceptible to antitumoral immunity by natural killer (NK) cells. Despite the functional impairment of PD-1<sup>+</sup> NK cells HL, underlying mechanisms cell dysfunction remain unclear. <b><i>Methods:</i></b> This study involved 14 HL patients and SNK10/KHYG-1 lines assess activation against cancer Activation...
In classical Hodgkin lymphoma (cHL), responsiveness to immune-checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant (NLPHL) not established. To gain insights into its potential NLPHL, we compared TME signatures between HLs using an integrative multiomic analysis. A discovery/validation approach 121 NLPHL 114 cHL patients highlighted >2-fold enrichment programmed cell death-1 (PD-1)...
Here, we present a novel case of patient with chronic lymphocytic leukemia (CLL) who received CTLA-4 and then PD-1 immune-checkpoint blockade (ICB) as treatment for concomitant metastatic melanoma. Whereas the melanoma was responsive to ICB, CLL rapidly progressed (but responded ICB cessation ibrutinib). There were no new genetic mutational drivers explain altered clinical course. PD-1/PD-L1/PD-L2 CTLA-4/CD80/CD86 expression not increased in B cells, CD8+ or CD4+ T-cell subsets, monocytes....
Abstract Background We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role adjuvant rituximab and translational studies. Methods Patients with ESFL were to involved-field radiotherapy (IFRT) or IFRT plus 6-cycles cyclophosphamide/vincristine/prednisolone (IFRT+CVP). From 2006 was added IFRT+CVP (IFRT+R-CVP). Clinical multi-omic parameters evaluated. Findings validated two independent cohorts (99...
Introduction: The TROG99.03 represents the only randomised phase III trial of combined modality therapy (CMT) in limited-stage follicular lymphoma 'LSFL', reporting a prolonged progression-free survival (PFS) CMT arm (MacManus, JCO, 2018). Here, we report extended follow up this study providing mature data patients treated with rituximab-containing regimen and development new gene-expression based prognostic score. Methods: Patients LSFL, grade 1–3a were (1:1) to either involved-field...
Abstract Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma. Twenty to twenty‐five percent of FL patients have progression disease within 24 months. These may benefit from immunotherapy if intact antigen presentation present. Molecular mechanisms impairing major histocompatibility complex class‐I (MHC‐I) in remain undefined. Here, by sequencing 172 tumours, we found MHC‐I transactivator NLRC5 was frequent gene abnormality pathway. Pyrosequencing showed that epigenetic...
A diverse intratumoral T-cell receptor (TCR) repertoire is associated with improved survival in diffuse large B-cell lymphoma (DLBCL) treated rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. We explored the impact of TCR on interim PET (iPET) done after four cycles R-CHOP, relationships between and circulating repertoire, phenotypes expanded clonotypes.We sequenced third complementarity-determining region TCRβ tumor samples, blood at pre-therapy...
Abstract Hodgkin lymphoma (HL) comprises two distinct disease entities based on clinical, morphologic and genotypic characteristics. Relative to classical Lymphoma (cHL), nodular lymphocyte predominant (NLPHL) is rare, its tumor microenvironment (TME) very poorly characterized. With the exception of rituximab, there are no targeted treatments nor advances in treatment NLPHL for decades. Unlike cHL, utility immune-checkpoint blockade (ICB) has not been evaluated NLPHL. Diagnostic samples were...